Death · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus lower‐dose radiation showed no clear difference in death compared with same chemotherapy plus higher‐dose radiation (high certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus lower‐dose radiation showed no clear difference in progression/relapse compared with same chemotherapy plus higher‐dose radiation (high certainty).
1 finding from 1 review
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus involved‐field radiation showed no clear difference in secondary malignant neoplasms compared with same chemotherapy plus extended‐field radiation (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus involved‐field radiation showed no clear difference in death compared with same chemotherapy plus extended‐field radiation (high certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus involved‐field radiation showed no clear difference in progression/relapse compared with same chemotherapy plus extended‐field radiation (high certainty).
1 finding from 1 review
Overall survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy may leads to higher overall survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Progression‐free survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy may leads to higher progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse event (flu‐like symptoms) · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (flu‐like symptoms) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse effect: fatigue · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (fatigue) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Neurotoxicity · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (neurotoxicity) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Overall survival · people with metastatic CRC
Chemotherapy + bevacizumab leads to lower overall survival compared with chemotherapy (high certainty).
1 finding from 1 review
Progression‐free survival · people with metastatic CRC
Chemotherapy + bevacizumab leads to lower progression‐free survival compared with chemotherapy (high certainty).
1 finding from 1 review
Tumour response · people with metastatic CRC
Chemotherapy + bevacizumab leads to higher overall tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
Severe adverse effects · people with metastatic CRC
Chemotherapy + bevacizumab showed no clear difference in severe adverse effects compared with chemotherapy (low certainty).
1 finding from 1 review
Overall survival ( · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) showed no clear difference in overall survival ( compared with surgery followed by chemotherapy (PDS) (high certainty).
1 finding from 1 review
Progression‐free survival · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) showed no clear difference in progression‐free survival ( compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ stoma formation (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ stoma… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ bowel resection (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ bowel… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ postoperative G3+ events (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ postoperative… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related postoperative mortality (28 days to 6 months of surgery4) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) leads to lower surgically‐related postoperative mortality (28 days to 6 months of… compared with surgery followed by chemotherapy (PDS) (high certainty).
1 finding from 1 review